Navigation Links
International Panel of Experts Gather for Roundtable Consensus Regarding Multiple Myeloma Related Disease
Date:2/23/2009

LOS ANGELES, Feb. 23 /PRNewswire-USNewswire/ -- On Wednesday, February 25, 2009, the Institute for Myeloma and Bone Cancer Research (IMBCR) will host a roundtable discussion bringing leading scientists in the field of cancer research together to discuss monoclonal gammopathy of undetermined significance (MGUS). The event is being cochaired by James R. Berenson, MD, who is Medical and Scientific Director at the IMBCR and Robert A. Kyle, MD, who is Professor of Medicine at the Mayo Clinic.

The goal of this roundtable discussion is to develop a consensus statement to be published in a major medical journal related to all aspects regarding the evaluation, follow-up and treatment of patients at risk for MGUS and its associated bone loss and fracture.

Topics for discussion include: addressing important issues such as which patients should be screened and how often; specific types of work-ups for patients; diagnostic testing for evaluation of bone disease; treatment measures for patients with significant bone loss and fractures; and other potential studies to be conducted for this disease population.

The event will take place February 25th at the Marriott Wardman Park Hotel just prior to the 12th Annual International Myeloma Workshop in Washington, D.C.

MGUS is a common condition in which a monoclonal paraprotein is detected in the blood and/or urine but these patients do not have a malignant disorder associated with the presence of this protein. More than 3% of individuals over 50 years of age and 5% of individuals over 70 have this condition. Studies show these individuals have an increased risk to develop cancers including myeloma and lymphoma with a very high risk of bone loss and fractures. There is no current consensus on the work-up, follow-up and treatment of patients with MGUS.

The Institute for Myeloma and Bone Cancer Research is a non-profit organization headquartered in Los Angeles, California. IMBCR is the only independent cancer research institute working to find improved treatment and ultimately a cure for multiple myeloma and other blood cancers. Drs. Berenson, Kyle and the IMBCR research team have been published in most major oncology journals such as the New England Journal of Medicine, Mayo Clinic Proceedings, BLOOD, Journal of Clinical Oncology, Science, Proceedings of the National Academy of Sciences, Cancer, Clinical Cancer Research, Clinical Lymphoma and Myeloma, Nature, Oncogene and the British Journal of Haematology. www.imbcr.org

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

James R. Berenson, MD

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=86038


'/>"/>
SOURCE Institute for Myeloma and Bone Cancer Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. International study strengthens case for daily calcium pill
2. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
3. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
4. LCA Hails International Investigators Studying Lung Cancer
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. PRA International Adds Dr. Susan Stansfield as Executive Vice President
7. Medical Services International Maintains Pace in Second Quarter
8. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
9. International Gateway Insurance Brokers Partners With MEDILINQ
10. Tulane University to receive $14M for international HIV/AIDS program
11. International Database Seeks to Boost Treatment of Altitude Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 02, 2016 , ... Two years ago, Arizona State University ... live by 1 million viewers and won numerous honors, including the region’s top ... the Walter Cronkite School of Journalism and Mass Communication are following up their ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... the launch of its 60-day free trial program for all of the company’s ... the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of two ostomy patients, standing as living proof that attitude and determination can ... diseases and issues that spike around the holidays. This campaign will offer patients ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference will ... Spa in Honolulu, offering local frontline clinicians the opportunity to extend their certified ... demand for supplemental training related to pain management has surged dramatically in recent ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... "Pro3rd Accents ... FCPX editors to create versatile lower third titles with just a few clicks of ... Accents Volume 2 includes 30 lower third animations. Choose from various styles with accented ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... ALEXANDRIA, Va. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... year by the Academy of Managed Care Pharmacy ... care organizations can better address the opioid addiction ... Medication Assisted Therapies (MAT). ATAG,s newly ... in Improving Access to Naloxone," addresses many issues ...
(Date:12/2/2016)... 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today announced ... ("PSI").  The combination of Texas -based Maxor ... PSI bring together both company,s clinical expertise and high-touch patient ... industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... , Dec. 2, 2016 CVS Health Corporation ... Analyst Day in New York City on Thursday, December 15, 2016, beginning ... leadership team will provide an in-depth review of the ... value. The company will also discuss 2017 earnings guidance ... webcast of the event will be broadcast simultaneously on ...
Breaking Medicine Technology: